All In Biotech

Drug Trial Radar · NCT00869635

S-1 and Photodynamic Therapy in Cholangiocarcinoma

Photodynamic Therapy With S-1 in the Patients With Unresectable Type III or IV Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control

Last checked: Nov 19, 2026Latest source record: Feb 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

43

Actual

Start

Feb 2009

Primary completion

Jul 2013

Study completion Aug 2013

Sponsor

Lead sponsor
Asan Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 26, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In patients with unresectable perihilar cholangiocarcinoma, photodynamic therapy with biliary stent has been known for palliation of jaundice and improving survival. But most of therapeutic effects were expected to delay bile duct obstruction rather than to decrease the tumor. Recently orally available chemotherapeutic agent, S-1 was reported as effective in patients with bile duct adenocarcinoma. The investigators' aims of study evaluate the combined effect of photodynamic therapy and S-1.

Conditions

  • Cholangiocarcinoma

Interventions

  • S-1 ChemotherapyDrug

    S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, \<1.25m2: 80mg/day, 1.25\~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment

  • Photodynamic therapyProcedure

    PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation

  • Systemic chemotherapy except S-1Procedure

    Variable systemic chemotherapy except S-1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare overall survival time in patients with unresectable perihilar cholangiocarcinoma treated with photodynamic therapy combined with or without S-1Time frame: 12 months after study start

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.